Cargando…
Evidence-based review and appraisal of the use of droperidol in the emergency department
Droperidol is a short-acting, potent dopamine D2 antagonist that can pass through the blood–brain barrier. A black box warning was issued for droperidol by the United States Food and Drug Administration in 2001 because of a risk of development of torsades de pointes induced by QT prolongation. Many...
Autores principales: | Lai, Pei-Chun, Huang, Yen-Ta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883829/ https://www.ncbi.nlm.nih.gov/pubmed/29643708 http://dx.doi.org/10.4103/tcmj.tcmj_195_17 |
Ejemplares similares
-
Retrospective Review of the Efficacy of Droperidol Compared to Prochlorperazine for Headache Management in the Emergency Department
por: Driller, Gabrielle K, et al.
Publicado: (2023) -
Economic Evaluation of Midazolam–Droperidol Combination, Versus Droperidol or Olanzapine for the Management of Acute Agitation in the Emergency Department: A Within-Trial Analysis
por: Yap, Celene Y. L., et al.
Publicado: (2017) -
The Effects of the FDA Warning on the Use of Droperidol by U.S. Emergency Physicians
por: Richards, John R., et al.
Publicado: (2003) -
The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department
por: Cole, Jon B., et al.
Publicado: (2020) -
Ondansetron-droperidol combination vs. ondansetron or droperidol monotherapy in the prevention of postoperative nausea and vomiting
por: Matsota, Paraskevi, et al.
Publicado: (2015)